Search results
Results from the WOW.Com Content Network
e. Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. [1][2] The first news report of Operation Warp Speed was on April 29, 2020, [3][4][5] and the program was ...
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in ...
v. t. e. The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [ 1 ] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. [ 32 ] It contains a recombinant spike protein from the SARS-CoV-2 Omicron variant lineage JN.1.
In a study examining COVID-19 infections, hospitalizations, and deaths in Nebraska after vaccination with the 2023-2024 vaccines that targeted the XBB.1.5 variant, researchers found that vaccine ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States.The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
Boxes of AstraZeneca's COVID-19 vaccine from India are delivered in Brazil (January 2021). Coordination of international air cargo is an essential component of time- and temperature-sensitive distribution of COVID‑19 vaccines, but, as of September 2020, the air freight network is not prepared for multinational deployment.
The updated vaccine targets the JN.1 variant, which is slightly older than KP.2, but the company reported data that showed the vaccine provides immunity against multiple variant strains recently ...
e. COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022. [2][3] On September 29, 2021, Codagenix presented positive phase 1 data for COVI-VAC ...